Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849155 · ClinicalTrials.gov registry record
Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition
A clinical trial of Genetic Predisposition, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT05849155: Recruiting study of Genetic Predisposition, sponsored by St. Jude Children's Research Hospital.
NCT05849155 is a study of Genetic Predisposition that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 125 participants, below the 3,511-participant average among 14 other Genetic Predisposition trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05849155, a study of Genetic Predisposition, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
Testing children, adolescents, and young adults (CAYA) for a genetic risk for cancer can help with early prevention and detection of cancers through regular follow-ups and medical care. After receiving genetic test results, CAYA may not accurately understand what their results mean, and parents are often unsure about talking with their CAYA about their genetic risk for cancer. By understanding how parents communicate with their CAYA, the investigators can improve future genetic education to reduce cancer risk. Primary Objectives: * Identify qualities of parent-CAYA (child, adolescent, and young adults) communication about CAYAs' genomic cancer risk, and their association with CAYAs' psychosocial and prevention outcomes. * Examine the association between sociodemographic, cancer-related, and psychosocial factors and parent-CAYA communication regarding CAYAs' genomic risk for cancer. * Identify barriers and facilitators of parent-CAYA communication regarding CAYAs' genomic risk for cancer.
Primary Outcome
Multiple regression models will be conducted to assess whether demographic and clinical factors significantly relate to quality and style of observed communication variables, as assessed using the Iowa Family Interaction Rating Scales. Multiple regression models will also be conducted to investigate whether general family communication, parent adjustment, parent genetic knowledge, parent sense of efficacy, and perception of children as less vulnerable (as assessed by parent and CAYA reported me
Conditions Studied
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2028-10 |
What NCT05849155 shows while recruiting
NCT05849155 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 3,511-participant average among 14 other Genetic Predisposition trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Genetic Predisposition appearing as the primary indexed condition, and to 0 interventions.
NCT05849155 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05849155 about?
NCT05849155 is a clinical study titled "Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition". Testing children, adolescents, and young adults (CAYA) for a genetic risk for cancer can help with early prevention and detection of cancers through regular follow-ups and medical care. After receiving genetic test results, CAYA may not accurately understand what their results mean, and parents are ...
What is the current status of trial NCT05849155?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2023-12-12. Estimated completion is 2028-10.
What conditions does trial NCT05849155 study?
This clinical trial studies the following conditions: Genetic Predisposition.
Who is sponsoring clinical trial NCT05849155?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849155 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Predisposition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05849155's enrollment target sits among peer trials
125 10th of 14 higher than 4 of 14 other Genetic Predisposition trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Predisposition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
RECRUITING
-
Vascular Disease Discovery Protocol
RECRUITING
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
RECRUITING
-
Pancreatic Cancer Early Detection Consortium
RECRUITING
-
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI